Reversal of hypogonadotropic hypogonadism with tamoxifen in a patient with hyperprolactinemia resistant to dopamine agonists

Fertility and Sterility

Volumn 84, Issue 3, 2005, Pages 756.e11-756.e14

  López, José M ^a,b   Oestreicher, Eveline ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

Dopamine agonists; Hyperprolactinemia; Hypogonadotropic hypogonadism; Tamoxifen

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; ESTRADIOL VALERATE; ESTROGEN; FOLLITROPIN; NOMEGESTROL; PROGESTERONE; PROLACTIN; QUINAGOLIDE; TAMOXIFEN;

ADULT; AMENORRHEA; ARTICLE; CASE REPORT; CHRONIC DISEASE; DRUG RESPONSE; ESTRADIOL BLOOD LEVEL; ESTROGEN THERAPY; FEMALE; FOLLITROPIN BLOOD LEVEL; HUMAN; HUMAN TISSUE; HYPERPROLACTINEMIA; HYPOGONADOTROPIC HYPOGONADISM; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; PROLACTIN BLOOD LEVEL;

EID: 24944577487     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2005.05.006     Document Type: Article

References (19)

1. s and stimulate adenylcyclase in human pituitary tumors. Nature 1989;340:692-6.
2. Barlier A, Pellegrini-Bouillier I, Caccavelli L, Gunz G, Morange-Ramos I, Jacquet P, et al. Abnormal transduction mechanisms in pituitary adenomas. Horm Res 1997;47:4-6, 227-34.
3. Pellegrini I, Rasolonjanahary R, Gunz G, Bertrand P, Delivet S, Jedynak CP, et al. Resistance to bromocriptine in prolactinomas. J Clin Endocrinol Metab 1989;69:500-9.
4. Molitch ME. Dopamine resistance of prolactinomas. Pituitary 2003;6:19-27.
5. Pickett CA. Diagnosis and management of pituitary tumors: recent advances. Prim Care 2003;30:765-89.
6. Colao A. Prolactinomas, resistant to standard dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab 1997;82:876-83.
7. Duranteau L, Chanson P, Lavoinne A, Horlait S, Lubetzki J, Kunh JM. Effect of the new dopaminergic agonist CV 205-502 on plasma prolactin levels and tumour size in bromocriptine-resistant prolactinomas. Clin Endocrinol 1991;34:25-9.
8. Brue T, Pellegrini I, Gunz G, Morange I, Dewailly D, Brownell J, et al. Effects of the dopamine agonist CV205-5022 in human prolactinomas resistant to bromocriptine. J Clin Endocrinol Metab 1992;74:577-84.
9. Zormitzki T, Knobler H, Nass D, Hadani M, Shimon I. Increased MIB-1/Ki-67 labeling index as a predictor of an aggressive course in a case of prolactinoma. Horm Res 2004;61:111-6.
10. López JM, Fardella C. Bromocriptine therapy and hyperprolactinemia [letter]. Ann Intern Med 1987;106:909.
11. Nicoll CS, Meites J. Estrogen stimulation of prolactin production by rat adenohypophysis in vitro. Endocrinology 1962;70:272-7.
12. Raymond V. Potent antidopaminergic activity of estradiol at the pituitary level on prolactin release. Science 1978;200:1173-5.
13. Kaptain GJ, Simmons NE, Alden TD, Lopes MB, Vance ML, Laws ER. Estrogen receptors in prolactinomas: a clinico-pathological study. Pituitary 1999;1:91-8.
14. Chaidarun SS, Swearingen B, Alexander JM. Differential expression of estrogen receptor β (ER-beta) in human pituitary tumors: functional interactions with ER α and a tumor-specific splice variant. J Clin Endocrinol Metab 1998;83:3308-15.
15. Cohen-Becker IR. Hyperprolactinemia alters frequency and amplitude of pulsatile LH secretion in the ovariectomized rat. Neuroendocrinology 1986;42:328-33.
16. Sakamoto H, Den K, Kondo Y, Tsubata K, Takagi S. Evidence that estrogen may be a key factor in hyperprolactinemic anovulation: a case report. Am J Obstet Gynecol 1987;157:318-9.
17. De Quijada M, Timmermans HA, Lamberts SW. Tamoxifen suppresses both the growth of prolactin-secreting pituitary tumours and normal prolactin synthesis in the rat. J Endocrinol 1980;86:109-16.
18. Jordan VC. Inhibition of estrogen-stimulated prolactin release by antioestrogens. J Endocrinol 1975;65:151-2.
19. Völker W. Impaired pituitary response to bromocriptine suppression: reversal after bromocriptine plus tamoxifen. Acta Endocrinol 1996;(Suppl 240):71-2.